Table 1.

Characteristics of total study population and by HBV screening status.

		Screened for HBV
Characteristic (n, %)	Total (n=4,008)	No (n=2137, 53.3%)	Yes (n=1871, 46.7%)	P value
Age, yrs, mean (SD)	58 (18.4)	62.07 (18.2)	53.36 (17.6)	< 0. 001
Male	2047 (51)	1018 (49.7)	1029 (50.3)	< 0.001
History of HBV	107 (2.7)	12 (11.2)	95 (88.8)	< 0.001
Race				< 0.001
White	3001 (74.9)	1686 (56.2)	1315 (43.8)
Hispanic	198 (4.9)	84 (42.4)	114 (57.6)
Black	285 (7.1)	123 (43.2)	162 (56.8)
Asian	410 (10.2)	181 (44.1)	229 (55.9)
Other	114 (2.8)	63 (55.3)	51 (44.7)
Primary disease				< 0.001
Solid Tumor	1649 (41.1)	1218 (73.9)	431 (26.1)
Liquid Tumor	1045 (26.1)	475 (45.5)	570 (54.5)
IBD	233 (5.8)	155 (66.5)	78 (33.5)
Rheumatologic	267 (6.7)	124 (46.4)	143 (53.6)
Psoriasis	73 (1.8)	28 (38.4)	45 (61.6)
Organ Transplant	678 (16.9)	100 (14.8)	578 (85.3)
Other†	63 (1.6)	37 (58.7)	26 (41.3)
Diagnosis Year				< 0.001
Before 2008	1,445 (36.1)	948 (65.6)	497 (34.4)
2008 or After	2,563 (63.9)	1189 (46.4)	1374 (53.6)
Type of therapy				< 0.001
Chemotherapy (non-Rituximab)	2382 (59.4)	1531 (64.3)	851 (35.7)
Rituximab-based Therapy	348 (8.7)	180 (51.7)	168 (48.3)
Anti-TNF	247 (6.2)	136 (55.1)	111 (44.9)
Anti-Rejection	678 (16.9)	100 (14.7)	578 (85.3)
Other‡	353 (8.8)	190 (53.8)	163 (46.2)
Specialty provider				< 0.001
Oncologist	2695 (67.2)	1693 (62.8)	1002 (37.2)
Gastroenterologist	233 (5.8)	155 (66.5)	78 (33.5)
Rheumatologist	267 (6.7)	124 (46.4)	143 (53.6)
Dermatologist	73 (1.8)	28 (38.4)	45 (61.6)
Transplant	678 (16.9)	100 (14.8)	578 (85.2)
Neurologist or Hematologist	63 (1.6)	37 (58.7)	26 (41.3)

^†Idiopathic thrombocytopenia, autoimmune hemolytic anemia

^‡Methotrexate, 6-mercaptopurine, azathioprine, plaquenil.